Have a feature idea you'd love to see implemented?
Let us know!
KPTI Karyopharm Therapeutics Inc
Price (delayed)
$0.816
Market cap
$101.74M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.83
Enterprise value
$212.26M
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related
Highlights
The EPS has grown by 43% YoY and by 35% from the previous quarter
The net income has grown by 39% from the previous quarter and by 36% YoY
The equity has plunged by 85% YoY but it has grown by 22% from the previous quarter
Karyopharm Therapeutics's quick ratio has decreased by 28% YoY but it has increased by 20% from the previous quarter
KPTI's debt is up by 11% from the previous quarter and by 10% YoY
Key stats
What are the main financial stats of KPTI
Market
Valuations
Earnings
Shares outstanding
124.68M
Market cap
$101.74M
Enterprise value
$212.26M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
0.68
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.46
Revenue
$145.67M
EBIT
-$62.52M
EBITDA
-$62.19M
Free cash flow
-$130.53M
Per share
Balance sheet
Liquidity
EPS
-$0.83
Free cash flow per share
-$1.08
Book value per share
-$1.12
Revenue per share
$1.2
TBVPS
$1.77
Total assets
$213.98M
Total liabilities
$346.12M
Debt
$195.63M
Equity
-$132.14M
Working capital
$150.92M
Debt to equity
-1.48
Current ratio
3.62
Quick ratio
3.31
Net debt/EBITDA
-1.78
Margins
Efficiency
Dividend
EBITDA margin
-42.7%
Gross margin
96%
Net margin
-61.7%
Operating margin
-89.9%
Return on assets
-38.7%
Return on equity
N/A
Return on invested capital
-21.1%
Return on capital employed
-40%
Return on sales
-42.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
KPTI stock price
How has the Karyopharm Therapeutics stock price performed over time
Intraday
-3.81%
1 week
-4.45%
1 month
16.02%
1 year
-12.12%
YTD
-5.66%
QTD
-1.69%
Financial performance
How have Karyopharm Therapeutics's revenue and profit performed over time
Revenue
$145.67M
Gross profit
$139.9M
Operating income
-$130.95M
Net income
-$89.91M
Gross margin
96%
Net margin
-61.7%
KPTI's net margin is up by 41% from the previous quarter and by 36% YoY
The net income has grown by 39% from the previous quarter and by 36% YoY
KPTI's operating income is down by 4.6% YoY
KPTI's operating margin is down by 4.9% YoY but it is up by 4.7% QoQ
Growth
What is Karyopharm Therapeutics's growth rate over time
Valuation
What is Karyopharm Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
0.68
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.46
The EPS has grown by 43% YoY and by 35% from the previous quarter
The equity has plunged by 85% YoY but it has grown by 22% from the previous quarter
The P/S is 90% lower than the 5-year quarterly average of 6.6 and 24% lower than the last 4 quarters average of 0.9
The revenue has grown by 3.7% from the previous quarter
Efficiency
How efficient is Karyopharm Therapeutics business performance
The ROS has soared by 51% from the previous quarter and by 47% YoY
Karyopharm Therapeutics's return on invested capital has increased by 46% QoQ and by 42% YoY
KPTI's ROA is up by 33% QoQ and by 17% YoY
Dividends
What is KPTI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for KPTI.
Financial health
How did Karyopharm Therapeutics financials performed over time
KPTI's total assets is 38% smaller than its total liabilities
Karyopharm Therapeutics's quick ratio has decreased by 28% YoY but it has increased by 20% from the previous quarter
KPTI's total assets is down by 28% year-on-year but it is up by 4.7% since the previous quarter
The equity has plunged by 85% YoY but it has grown by 22% from the previous quarter
KPTI's debt to equity is down by 42% since the previous quarter but it is up by 41% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.